HRP970699B1 - Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms - Google Patents
Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline formsInfo
- Publication number
- HRP970699B1 HRP970699B1 HR970699A HRP970699A HRP970699B1 HR P970699 B1 HRP970699 B1 HR P970699B1 HR 970699 A HR970699 A HR 970699A HR P970699 A HRP970699 A HR P970699A HR P970699 B1 HRP970699 B1 HR P970699B1
- Authority
- HR
- Croatia
- Prior art keywords
- crystallisation
- crystalline forms
- resulting crystalline
- naphth
- trifluoromethylphenyl
- Prior art date
Links
- 238000002425 crystallisation Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical class C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- WVHBEIJGAINUBW-UHFFFAOYSA-N Xaliproden hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WVHBEIJGAINUBW-UHFFFAOYSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- WJJYZXPHLSLMGE-UHFFFAOYSA-N xaliproden Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WJJYZXPHLSLMGE-UHFFFAOYSA-N 0.000 abstract 2
- 230000008025 crystallization Effects 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000010992 reflux Methods 0.000 abstract 1
- 238000003756 stirring Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9615904A FR2757543B1 (fr) | 1996-12-23 | 1996-12-23 | Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP970699A2 HRP970699A2 (en) | 1998-10-31 |
| HRP970699B1 true HRP970699B1 (en) | 2007-03-31 |
Family
ID=9499043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR970699A HRP970699B1 (en) | 1996-12-23 | 1997-12-22 | Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms |
Country Status (39)
| Country | Link |
|---|---|
| EP (1) | EP0950050B1 (xx) |
| JP (2) | JP4499188B2 (xx) |
| KR (1) | KR100586670B1 (xx) |
| CN (1) | CN1129580C (xx) |
| AR (1) | AR009672A1 (xx) |
| AT (1) | ATE307802T1 (xx) |
| AU (1) | AU736697B2 (xx) |
| BR (1) | BR9714081A (xx) |
| CA (1) | CA2275596C (xx) |
| CO (1) | CO5070688A1 (xx) |
| CZ (1) | CZ296689B6 (xx) |
| DE (1) | DE69734460T2 (xx) |
| DK (1) | DK0950050T3 (xx) |
| DZ (1) | DZ2383A1 (xx) |
| EE (1) | EE04188B1 (xx) |
| EG (1) | EG21567A (xx) |
| ES (1) | ES2251038T3 (xx) |
| FR (1) | FR2757543B1 (xx) |
| HK (1) | HK1024002A1 (xx) |
| HR (1) | HRP970699B1 (xx) |
| HU (1) | HU227425B1 (xx) |
| IL (1) | IL129938A (xx) |
| IN (1) | IN186976B (xx) |
| IS (1) | IS2357B (xx) |
| MY (1) | MY118015A (xx) |
| NO (1) | NO312364B1 (xx) |
| NZ (1) | NZ336130A (xx) |
| PL (1) | PL190494B1 (xx) |
| RS (1) | RS49882B (xx) |
| RU (1) | RU2192416C2 (xx) |
| SA (1) | SA98180971B1 (xx) |
| SI (1) | SI0950050T1 (xx) |
| SK (1) | SK285088B6 (xx) |
| TR (1) | TR199901363T2 (xx) |
| TW (1) | TW518322B (xx) |
| UA (1) | UA60324C2 (xx) |
| UY (1) | UY24825A1 (xx) |
| WO (1) | WO1998028271A1 (xx) |
| ZA (1) | ZA9711576B (xx) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2757543B1 (fr) * | 1996-12-23 | 1999-04-02 | Sanofi Sa | Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues |
| FR2782082B3 (fr) * | 1998-08-05 | 2000-09-22 | Sanofi Sa | Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose |
| US9272068B2 (en) | 2010-03-12 | 2016-03-01 | Nippon Shokubai Co., Ltd. | Process for producing water-absorbing resin |
| KR101879468B1 (ko) * | 2011-04-15 | 2018-07-17 | 엠큐어 파마슈티컬즈 리미티드 | 릴피비린 중간체의 제조를 위한 공정 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2531707A1 (fr) * | 1982-08-16 | 1984-02-17 | Midy Spa | Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques |
| FR2757543B1 (fr) * | 1996-12-23 | 1999-04-02 | Sanofi Sa | Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues |
-
1996
- 1996-12-23 FR FR9615904A patent/FR2757543B1/fr not_active Expired - Fee Related
-
1997
- 1997-12-19 AR ARP970106029A patent/AR009672A1/es not_active Application Discontinuation
- 1997-12-22 HR HR970699A patent/HRP970699B1/xx not_active IP Right Cessation
- 1997-12-22 MY MYPI97006233A patent/MY118015A/en unknown
- 1997-12-22 DZ DZ970233A patent/DZ2383A1/xx active
- 1997-12-23 UA UA99063521A patent/UA60324C2/uk unknown
- 1997-12-23 IL IL12993897A patent/IL129938A/en not_active IP Right Cessation
- 1997-12-23 EP EP97952986A patent/EP0950050B1/fr not_active Expired - Lifetime
- 1997-12-23 TR TR1999/01363T patent/TR199901363T2/xx unknown
- 1997-12-23 CO CO97074792A patent/CO5070688A1/es unknown
- 1997-12-23 CZ CZ0229299A patent/CZ296689B6/cs not_active IP Right Cessation
- 1997-12-23 PL PL97334256A patent/PL190494B1/pl not_active IP Right Cessation
- 1997-12-23 SI SI9730720T patent/SI0950050T1/sl unknown
- 1997-12-23 WO PCT/FR1997/002393 patent/WO1998028271A1/fr active IP Right Grant
- 1997-12-23 EG EG138397A patent/EG21567A/xx active
- 1997-12-23 ES ES97952986T patent/ES2251038T3/es not_active Expired - Lifetime
- 1997-12-23 BR BR9714081-3A patent/BR9714081A/pt not_active Application Discontinuation
- 1997-12-23 DE DE69734460T patent/DE69734460T2/de not_active Expired - Lifetime
- 1997-12-23 RU RU99116597/04A patent/RU2192416C2/ru not_active IP Right Cessation
- 1997-12-23 CN CN97180863A patent/CN1129580C/zh not_active Expired - Fee Related
- 1997-12-23 AU AU56684/98A patent/AU736697B2/en not_active Ceased
- 1997-12-23 IN IN3761DE1997 patent/IN186976B/en unknown
- 1997-12-23 UY UY24825A patent/UY24825A1/es not_active IP Right Cessation
- 1997-12-23 DK DK97952986T patent/DK0950050T3/da active
- 1997-12-23 CA CA002275596A patent/CA2275596C/en not_active Expired - Fee Related
- 1997-12-23 SK SK828-99A patent/SK285088B6/sk not_active IP Right Cessation
- 1997-12-23 HU HU0001387A patent/HU227425B1/hu not_active IP Right Cessation
- 1997-12-23 EE EEP199900264A patent/EE04188B1/xx not_active IP Right Cessation
- 1997-12-23 RS YUP-289/99A patent/RS49882B/sr unknown
- 1997-12-23 NZ NZ336130A patent/NZ336130A/xx not_active IP Right Cessation
- 1997-12-23 JP JP52848198A patent/JP4499188B2/ja not_active Expired - Fee Related
- 1997-12-23 AT AT97952986T patent/ATE307802T1/de active
- 1997-12-23 KR KR1019997005373A patent/KR100586670B1/ko not_active IP Right Cessation
- 1997-12-23 ZA ZA9711576A patent/ZA9711576B/xx unknown
-
1998
- 1998-01-21 TW TW086119629A patent/TW518322B/zh not_active IP Right Cessation
- 1998-03-11 SA SA98180971A patent/SA98180971B1/ar unknown
-
1999
- 1999-06-10 IS IS5076A patent/IS2357B/is unknown
- 1999-06-22 NO NO19993076A patent/NO312364B1/no not_active IP Right Cessation
-
2000
- 2000-06-01 HK HK00103287A patent/HK1024002A1/xx not_active IP Right Cessation
-
2009
- 2009-05-07 JP JP2009112971A patent/JP2009197022A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE240314T1 (de) | Kristalle von benzimidazolderivate und verfahren zu ihrer herstellung | |
| NO973635L (no) | Fremgangsmåte for hemming av celle-celle adhesjon | |
| DE69330963T2 (de) | Herstellung von aluminosilikatzeolithen | |
| NZ199990A (en) | 1,4-dihydropyridine derivatives and pharmaceutical compositions | |
| NO20022558L (no) | 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor | |
| JPS57171968A (en) | 1,4-dihydropyridine derivative | |
| DE69218330T2 (de) | Verfahren zur Herstellung von an 4-Position substituierten 1,4-Dihydropyridinen | |
| ES2093399T3 (es) | Nuevos derivados de acido fosfono-succinico, procedimiento para su preparacion y medicamentos que contienen estos compuestos. | |
| DE69615341D1 (de) | Verfahren zur herstellung von paraxylol, das wenigstens eine kristallisierungsstufe auf hoher temperatur und eine stufe zum partiellen schmelzen der kristalle enthaelt | |
| DE69311837T2 (de) | Steroide zur Behandlung von Prostatisch-Hypertrophe, ihre Herstellung und Verwendung | |
| NO174624C (no) | Cyklopropylmalonanilatderivat for hemming av plantevekst, planteveksthemmende preparat og anvendelse derav | |
| HRP970699B1 (en) | Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms | |
| ATE518835T1 (de) | Kristallform einer chinolinverbindung und verfahren zu deren herstellung | |
| AT379590B (de) | Verfahren zur herstellung von neuen 4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridinderivaten | |
| JPS6471816A (en) | Pharmacologically useful polymetamorphosis of buspirone | |
| NO922521L (no) | Piperidinyletanolderivater med terapeutisk virkning | |
| DE3867281D1 (de) | Calcium-4,6-dioxo-4h-pyrano(3,2-g)-chinolin-2,8-dicarboxylat-derivat, verfahren zu seiner herstellung und dieses enthaltende zusammensetzungen. | |
| DK535284A (da) | Phenylalkansyrederivater og fremgangsmaade til fremstilling deraf | |
| YU46961B (sh) | Postupak za konverziju polimorfnog kristalnog oblika buspiron hlorhidrata | |
| NO955242L (no) | Piperidinderivater, fremgangsmåte for fremstilling derav og deres terapeutiske anvendelse | |
| PH21322A (en) | Anti-imflammatory polymorphic monoethanolamine salt of n-(2-pyridyl)-2-methyl-4-hydroxy-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound; composition and method of use therefor | |
| EE9700292A (et) | Asendatud fenüülamidiinid, neid ühendeid sisaldavad ravimid ja meetod nende valmistamiseks | |
| DE3873824T2 (de) | Verfahren zur herstellung von alpha-(alkylphenyl)-4-(hydroxydiphenylmethyl)-1-piperidinbutanol. | |
| NO973103L (no) | Fremgangsmåte for inhibering av veksthormoneffekter | |
| DE3674117D1 (de) | Verfahren zur herstellung von 1,4-dihydropyridinderivaten ueber neue zwischenprodukte. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| PPPP | Transfer of rights |
Owner name: SANOFI-SYNTHELABO, FR |
|
| PNAN | Change of the applicant name, address/residence |
Owner name: SANOFI-AVENTIS, FR |
|
| B1PR | Patent granted | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20111217 Year of fee payment: 15 |
|
| PBON | Lapse due to non-payment of renewal fee |
Effective date: 20121223 |